Keywords
FluoxetineNeurochemicalAntidepressantTricyclicAnimal models of depressionPharmacologySerotoninDepression (economics)PsychiatryDrugMedicineAnimal studiesPsychologyNeuroscienceReceptorInternal medicineAnxiety
Affiliated Institutions
Related Publications
Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder
A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessi...
Treatment-resistant depression in the age of serotonin: evolving strategies
Serotonin specific reuptake inhibitor antidepressants (SSRIs) have become the de facto first line treatment in pharmacotherapy of major depression. Albeit SSRIs have the advanta...
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of anxiety and depression, which is now in Phase III cli...
Publication Info
- Year
- 1995
- Type
- review
- Volume
- 57
- Issue
- 5
- Pages
- 411-441
- Citations
- 639
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
639
OpenAlex
Cite This
David T. Wong,
Frank P. Bymaster,
Eric A. Engleman
(1995).
Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication.
Life Sciences
, 57
(5)
, 411-441.
https://doi.org/10.1016/0024-3205(95)00209-o
Identifiers
- DOI
- 10.1016/0024-3205(95)00209-o